Drug

Carboplatin

In clinical development

Actively researchedLate-stage developmentSteady momentum

Also known as CBDCA, Kyxata, Paraplatin, Carboplatine+5 more

CBDCA, Kyxata, Paraplatin, Carboplatine, Carboplatino, Carboplatinum, Cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II), Cis-diammine(1,1-cyclobutanedicarboxylato)platinum, Cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II).

RxNorm40048 ChEMBLCHEMBL1351 ATCL01XA02UNIIBG3F62OND5

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Open-Label, Multi-Cohort Study of Fluzoparib Monotherapy or in Combination With Bevacizumab as Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )

Clinical trial2026-07-27Results posted · ClinicalTrials.gov

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Clinical trial2026-07-24Results expected Q4 2030 · ClinicalTrials.gov

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Clinical trial2026-07-24Results expected Q2 2027 · ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Clinical trial2026-07-20Results expected Q2 2030 · ClinicalTrials.gov

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

Clinical trial2026-07-20Results expected Q4 2028 · ClinicalTrials.gov

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Clinical trial2026-07-20Results expected Q4 2027 · ClinicalTrials.gov

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

Clinical trial2026-07-17Results expected Q4 2029 · ClinicalTrials.gov

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Research2024-08-22Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

Research2024-03-01The New England journal of medicine

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.

Research2024-02-01JAMA oncology

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.

Research2023-11-01Clinical cancer research : an official journal of the American Association for Cancer Research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Carboplatin

Aliases & brands

CBDCAKyxataParaplatinCarboplatineCarboplatinoCarboplatinumCis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)Cis-diammine(1,1-cyclobutanedicarboxylato)platinumCis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)

RxNorm CUI

40048

ChEMBL ID

CHEMBL1351

ATC codes

L01XA02

UNII

BG3F62OND5

Clinical trials

198 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

198

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 198

Phase 131Phase 1 / 212Phase 294Phase 2 / 36Phase 348Phase 44Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).

CompletedPH IVMerck Sharp & Dohme LLCn=1012024

Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)

CompletedPH IVCelgenen=1432017

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

TerminatedPH IVMassachusetts General Hospitaln=152016

A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC)

CompletedPH IVNovartis Pharmaceuticalsn=492015

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

RecruitingPH II/IIIUniversity of Birminghamn=2102033

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

CompletedPH IIIMerck Sharp & Dohme LLCn=7392026

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

CompletedPH IINational Cancer Institute (NCI)n=4542025

A Multicenter, Prospective, Double-Cohort Phase II Clinical Study of Camrelizumab in Combination With Docetaxel and Platinum or Apatinib Mesylate as First-Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

CompletedPH IIShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universityn=812025

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

CompletedPH IIMerck Sharp & Dohme LLCn=1262025

Phase II Study of Pembrolizumab in Combination With Platinum-based Chemotherapy in Nonsmall Cell Lung Cancer Patients With Targetable Genetic Alterations Previously Treated With Appropriate Targeted Agents With Progressive Disease

CompletedPH IIUniversity of Michigan Rogel Cancer Centern=332025

A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)

CompletedPH IAstraZenecan=1052025

Research activity

32 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20052024

Most influential

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

The New England journal of medicine · 2009 · 6,372 cites

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

The New England journal of medicine · 2018 · 2,952 cites

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

The New England journal of medicine · 2018 · 2,697 cites

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

The New England journal of medicine · 2008 · 2,492 cites

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

The New England journal of medicine · 2014 · 2,470 cites

A phase 3 trial of bevacizumab in ovarian cancer.

The New England journal of medicine · 2011 · 1,607 cites

Related diseases

12 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Lung Neoplasms13 Carcinoma, Non-Small-Cell Lung9 Neoplasm Recurrence, Local5 Carcinoma, Squamous Cell4 Endometrial Neoplasms4 Ovarian Neoplasms3 Adenocarcinoma2 Anemia2 Carcinoma, Ovarian Epithelial2 Neoplasms, Glandular and Epithelial2 Small Cell Lung Carcinoma2 Urologic Neoplasms2

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Paclitaxel

Studied across 14 of the same disease areas as Carboplatin in the shared literature.

13 shared papers14 shared diseases

Cisplatin

Studied across 16 of the same disease areas as Carboplatin in the shared literature.

16 shared diseases8 shared papers

Atezolizumab

Studied across 11 of the same disease areas as Carboplatin in the shared literature.

11 shared diseases8 shared papers

Pembrolizumab

Studied across 16 of the same disease areas as Carboplatin in the shared literature.

16 shared diseases4 shared papers

Gemcitabine

Studied across 9 of the same disease areas as Carboplatin in the shared literature.

9 shared diseases3 shared papers

Fluorouracil

Studied across 11 of the same disease areas as Carboplatin in the shared literature.

11 shared diseases1 shared paper

Deoxycytidine

Studied across 7 of the same disease areas as Carboplatin in the shared literature.

7 shared diseases2 shared papers

Pemetrexed

Studied across 4 of the same disease areas as Carboplatin in the shared literature.

4 shared diseases3 shared papers

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials